> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Panel Backs OTC Switch for Acne Drug
- URL: https://www.fdaweb.com/fda-panel-backs-otc-switch-for-acne-drug/
- Published: 2016-04-18T12:00:00.000Z
- Updated: 2026-09-14T20:55:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135394

> FDA’s Nonprescription Drugs Advisory Committee has unanimously (12 to 0) voted to support approval for a Galderma Labs application seeking over-the-counter marketing of Differin (adapalene gel 0.1%) for treating acne in consumers ages 12 years and older. Some panel members said that a proposed Drug Facts label should include a warning about its use in pregnant woman. But other members said such a warning was unnecessary and could cause alarm and confusion. Panel members also said the label should include a precaution for the drug’s use in nursing women to avoid children having contact with the areas where the product has been applied.